NVO - Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge Program Adjustments | Benzinga
Wednesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million.
Preliminary cell engineering and biosecurity revenue are expected to be within the disclosed guidance range of $145 million-$150 million and up to $110 million in 2023, respectively.
New Cell Programs are expected to be within the previously disclosed guidance range of 80-85 new Cell Programs added to the platform in 2023.
William Blair sees Ginkgo's recent update as positive despite reducing its full-year program target from 100.
The accelerated pace of program announcements is linked to a new success-based pricing model and operational enhancements.
Ginkgo also completed the program's ...